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Abstract (197 words) 
Despite its demonstrated clinical and economic effectiveness, access to Cognitive 
Behavioural Therapy for psychosis (CBTp) in routine practice remains low. The UK National 
Health Service (NHS England) Improving Access to Psychological Therapies for people with 
Severe Mental Illness (IAPT-SMI) initiative aims to address this problem. We report 14-
month outcomes for our psychosis demonstration site. 
Primary and secondary care and self-referrals were screened to check the suitability of the 
service for the person. Psychotic symptoms, distress, service use, functioning and satisfaction 
were measured before and after therapy, by trained assessors. User-defined wellbeing and 
goal-attainment were rated sessionally.  
Access to CBTp increased almost threefold (2011/12 accepted referrals/year n=106; 2012/13, 
n=300). The IAPT-SMI assessment protocol proved feasible and acceptable to service users, 
with paired primary outcomes for 97% of closed cases. Therapy completion (≥5 sessions) 
was high (83%) irrespective of ethnicity, age and gender. Preliminary pre-post outcomes 
showed clinical improvement and reduced service use, with medium/high effect sizes. User-
rated satisfaction was high. 
We conclude that individual psychological interventions for people with psychosis can be 
successfully delivered in routine services using an IAPT approach. High completion rates for 
paired outcomes demonstrate good user experience, clinical improvement, and potential 
future cost savings. 
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Introduction  
Psychosis is a mental health condition characterised by unusual experiences such as hearing 
voices that others cannot, or holding beliefs which others consider unusual. The experiences 
often cause significant distress and disability. Psychosis exacts a high societal cost (Andrew, 
Knapp, McCrone, Parsonage, & Trachtenberg, 2012), with increased risk of physical health 
problems, and early mortality (Chang et al., 2011). Medication is only partially effective: up 
to 40% of service users experience persistent distressing positive symptoms; over a third 
experience disabling concurrent affective disorders; and two thirds experience persisting 
negative symptoms of amotivation and apathy (National Institute for Health and Care 
Excellence, NICE, 2014). Suicide rates are up to twelve times greater compared to the 
general population (Dutta et al., 2010).  
 
Cognitive therapy for psychosis (CBTp) is an adaptation of CBT for emotional disorders, 
tailored to the specific needs of people with psychosis. It draws on cognitive models of 
psychosis to identify and intervene with the psychological processes that are maintaining 
distress and impeding recovery, and to promote an individualised and helpful understanding 
of the experience of psychosis. Therapy is tailored to personal recovery goals, and 
exceptional care is taken to foster a therapeutic relationship that is genuinely collaborative, 
empowering, and characterised by explicit warmth, positive regard, and transparency (e.g. 
Johns, Jolley, Keen, & Peters, 2014). 
 
There is robust evidence for the positive impact of CBTp on positive symptoms, distress and 
functioning compared to routine care. Improvement has been demonstrated in both formal 
research trials and routine services, with persistence of effects at follow-up and high service 
user satisfaction with therapy (e.g. NICE, 2014; Peters et al., 2010; Lincoln et al., 2012;  
Morrison et al., 2004; Miles, Peters, & Kuipers, 2007). There is, however, a need to 
strengthen the evidence base for CBTp compared to an alternative therapy and effect sizes 
remain modest (Jauhar et al., 2014).  
 
CBTp is cost-effective, resulting in net savings in healthcare costs of up to £2.3K, once the 
cost of providing therapy has been accounted for (NICE, 2014), arising primarily from 
reductions in the rate and duration of inpatient admissions. International clinical guidelines 
now recommend that people with psychosis are offered CBTp (Gaebel, Riesbeck, & 
Wobrock, 2011). In the UK, the updated NICE guidance recommends that people with 
psychosis are offered CBT at the earliest opportunity, prior to the onset of frank disorder, and 
at each recurrence of symptoms (NICE, 2014).   
 
Despite the powerful evidence base, and high levels of consumer demand, psychological 
therapies are not readily accessible for people with psychosis, with reported delivery rates in 
routine services of 10% (The Schizophrenia Commission, 2012). Key limiting factors include 
unclear referral pathways; prioritisation of other interventions; and restricted therapist 
capacity with poor access to training, support and supervision within services (e.g. Shafran et 
al., 2009). The UK Improving Access to Psychological Therapies for people with Severe 
Mental Illness (IAPT-SMI) pilot initiative is designed to identify and overcome these 
obstacles, building on the success of IAPT services for people with anxiety and depression 
(Clark et al., 2009; Gyani, Shafran, Layard, & Clark, 2013), as part of the Department of 
Health’s four-year plan to increase access to talking therapies (DH, 2011). There are six 
demonstration sites, offering NICE-recommended psychological therapies to people with 
bipolar affective disorder, personality disorders or psychosis. Here we report on the 
implementation of CBTp in the first operational year (1/11/12 to 31/12/13) of the South 
London and Maudsley NHS Foundation Trust (SLaM) psychosis demonstration site.  
 
Method 
Service context 
SLaM serves four London boroughs, each with high rates of diversity (50-60% Black and 
Minority Ethnic groups, Office for National Statistics, 2012), population movement, drug 
use, crime, socio-economic deprivation, and psychosis incidence. SLaM is part of the King’s 
Health Partners Academic Health Sciences Centre, and services are provided within Clinical 
Academic Groups (CAGs), with the aim of developing specialist practice. The Psychosis 
CAG provides care for about 7,000 people with psychosis, at all stages of the condition, 
across four Care Pathways: Early Intervention (EI), Promoting Recovery (PR), Complex 
Care, and Acute Inpatient Care. The IAPT-SMI pilot is overseen by PICuP (Psychological 
Interventions Clinic for oUtpatients with Psychosis) in the EI and PR pathways, operating 
alongside existing psychological therapy provision and the multidisciplinary Community 
Mental Health Teams (CMHTs). The PR pathway serves people with established 
schizophrenia spectrum diagnoses, or with psychotic symptoms in the context of bipolar 
affective disorder. The EI pathway sees people with a first presentation of psychotic 
symptoms, which may reach the criteria for a range of diagnoses. Psychological therapists in 
routine services work sessionally in IAPT-SMI and, together with four NHS England funded 
therapists, the full therapist complement of the service is ten whole time equivalents (UK 
Agenda for Change bandings 7 and 8).  All participants gave consent for their measures to be 
used pseudonymously, in aggregate, to evaluate the service, and the service evaluation was 
approved by SLaM’s audit and evaluation committee (ref. PSYCHLO-13-18).  
 
Referrals 
The IAPT-SMI service is designed for service users with psychosis whose needs can be 
appropriately met within a psychological therapy service (i.e. people who are likely to opt-in 
to a sensitively offered talking intervention and attend reasonably reliably, and who do not 
currently present with very high levels of risk or chaotic behaviour). Referrals are accepted 
from primary and secondary care, with a self-referral option. Medical and social care needs 
are managed by the CMHT or in primary care during therapy. 
 
Assessment 
All referrals are screened by clinicians within the service to ensure referral criteria are met. 
Accepted referrals are contacted by an independent assessor (a graduate psychology 
assistant), trained in discussing therapy sensitively and in making assertive attempts to 
engage service users. People choosing to opt-in to the service are offered a pre-therapy 
assessment at a time and location to suit them. Assessments usually take place over a single 
session, and therapists offer a first therapy appointment as soon as possible following 
assessment. Independent assessments are repeated at three-months and at the end of therapy. 
Sessional measures are completed at every meeting, providing the service user agrees, with 
the therapist’s help if needed. 
 
Therapy 
Therapy is offered flexibly to suit the person’s needs, aiming for a minimum of 16 sessions in 
line with NICE guidance, and a maximum of 30 sessions. Sessions last approximately an 
hour, and are usually offered at weekly to fortnightly intervals, over six to nine months. 
Therapy is individualised and formulation based, but adheres to published manuals and the 
CORE CBTp competence framework (Roth & Pilling, 2013) in terms of central principles, 
structure, and techniques employed. Location is flexible to suit the individual, but is usually 
in the referring team’s base or a central clinic. Supervision is provided weekly to fortnightly 
in groups of 3-6 therapists for 1.5 hours, with fortnightly to monthly individual supervision. 
Supervisors are senior clinicians with between 10 and 20 years of experience of training 
therapists and of providing therapy within randomised controlled trials. Therapists are trained 
to competence, using evidence-based assessments of adherence and competence (Fowler, 
Rollinson, & French, 2011); training is usually 12-24 months of post-qualification, 
postgraduate study (Jolley et al., 2013).  
 
Measures 
One of the demonstration site aims was to pilot routine outcome monitoring, including 
activity (referrals, waiting times, attendance); performance (clinical and functioning 
outcomes and service use); user experience and satisfaction. The IAPT-SMI clinical 
outcomes battery comprised the four measures listed below, together with patient experience, 
satisfaction and feedback questionnaires, and the Euroqol group’s EQ5D (1990) measure of 
Quality of Life, which will be reported in a separate economic analysis. We additionally 
report outcomes on the Clinical Outcomes in Routine Evaluation-10 (CORE-10; Barkham et 
al., 2013), which generates a mean total distress score based on ten items, each rated from 0 
to 4, ranging from 0 (low) to 40 (severe). Psychometrics are good, and changes of 5 points or 
more are considered reliable. Functional outcome was rated according to IAPT criteria as 
engaged in meaningful activity (in a work, domestic, voluntary or academic setting) or 
unoccupied. Demographic and service use data were collected by self-report and, for existing 
users of SLaM services, from the clinical record. Service use data collected during the first 14 
months comprised the duration of mental health inpatient admissions (occupied bed days, 
OBDs) and the number of days in contact with a crisis team (crisis team days, CTDs), 
calculated as a mean/person/month. Self-reported ethnicity was dichotomised into Black and 
Minority Ethnic (BME) or other group (non-BME). User experience was rated using six 
items on a five point scale from 1 (all of the time) to 5 (never), with a total score ranging 
from 6 (positive) to 30 (negative). Satisfaction was rated on a five point scale from 1 (very 
dissatisfied) through 3 (indifferent) to 5 (very satisfied). The Friends and Family Test (DH, 
2013) rated likelihood of recommending the service, from 1 (extremely likely) to 5 
(extremely unlikely). A pilot group of service users completed feedback specifically on the 
use of measures in the IAPT-SMI service, using a scale from 0 (extremely unhelpful) through 
5 (neither helpful nor unhelpful) to 10 (extremely helpful). 
 
IAPT-SMI clinical outcomes 
1. Choice of outcome in cognitive therapy for psychoses (CHOICE; Greenwood et al., 2010; 
2012) 
An 11-item shortened version of this user-defined outcome measure is completed sessionally. 
Each item is rated from 0 (worst) to 10 (best), yielding a mean total score ranging from 0 to 
10. Because of its high correlation with a range of measures of affective disturbance 
(Greenwood et al., 2010) and user-led design, the CHOICE was determined centrally and a 
priori as the primary outcome measure for the psychosis demonstration sites, and reliable 
improvement/deterioration similarly predetermined as a change of ≥1.45 in mean total score. 
The short version was developed specifically for the IAPT-SMI initiative, based on the 
highest loading items from the 34-item measure. Inter-rater, internal, and test-retest reliability 
for the new measure are all good, as is criterion validity (Greenwood et al., 2012).  
 
2. Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS, Tennant et al., 2007) 
Fourteen positively phrased items are rated from 1 (none of the time) to 5 (all of the time), 
yielding a total score ranging from 14 to 70. The authors report good internal consistency, 
test-retest reliability, content and criterion validity for mixed groups (Tennant et al., 2007). 
Sensitivity analyses suggest a change of three or more to represent meaningful clinical 
change (Maheswaran, Weich, Powell, & Stewart-Brown, 2012).   
 
3. Work and Social Adjustment Scale (WSAS, Mundt, Marks, Shear, & Greist, 2002) 
Five items rate functional impairment from 0 (low) to 8 (very severe) yielding a total score 
from 0-40. The authors report good psychometrics in a sample with affective disorders; with 
a score of 13 considered to represent reliable change.  
 
4. Psychotic Symptom Rating Scales (PSYRATS - Haddock, McCarron, Tarrier, & Faragher, 
1999).   
This multidimensional structured interview measure of voices (11 items) and delusions (6 
items) is completed only by individuals with a recent history of the relevant symptom (during 
the last month). Each item is rated for increasing severity from 0 to 4 over the last month. 
Psychometrics are very good, with perfect inter-rater reliability reported in the original 
development study (Haddock et al., 1999). Voices (0-44), delusions (0-24) and %PSYRATS 
((voices total/44 + delusions total/24) x 100) scores are reported.  
 
Analyses 
Descriptive statistics were calculated for all those attending an assessment. Total scores were 
prorated if two or fewer items were missing, and otherwise excluded, with sample size 
reported for each variable. Outcomes were reported for all closed cases from the start of the 
service on 1/11/12 to the reporting date of 31/12/13, comparing baseline to the most recent 
assessment (last session, end or three-month assessments). Therapy dropout was defined a 
priori according to IAPT-SMI agreed criteria, as attending fewer than five sessions. 
Demographic differences in completion rates and outcomes were investigated using both an 
eight category ‘access group’ variable (2x2x2; age >35 years/≤35 x BME/non-BME x 
gender) and BME status alone. Primary clinical outcome (CHOICE) and service use (OBDs, 
CTDs) data were collected for all cases; functioning, satisfaction and secondary clinical 
(CORE-10, WEMWBS, WSAS, PSYRATS) outcomes were collected for those attending a 
formal post-therapy assessment, and, for the PSYRATS only, those with a history of the 
relevant symptom. Paired-sample t-tests (McNemar test for the binary functional outcome 
variable) were used to assess the significance of change in outcomes (CHOICE mean score, 
service use (x2, OBDs, CTDs), functioning and the six secondary outcome measures) during 
the course of therapy and within-participant effect sizes (ES, Cohen’s d) were calculated 
using the pooled standard deviation (i.e. using pre and post means combined) to minimise 
inflation of effects. Chi-squared tests (ES: Cramer’s V), t-tests (using a Satterthwaite 
adjustment when the assumption of equality of variance was violated) and ANOVA (ES: 
Cohen’s d) were used to investigate variation in outcomes according to therapy 
completion/dropout (for CHOICE (mean score, reliable change) and service use only), 
current psychotic symptoms, access group, and BME status.  
 
Results 
Referrals and therapy completion 
Of all referrals for CBTp (n=367), the service was considered unsuitable for only 13% of 
cases (n=49). Reasons for referrals not being accepted were: i) no psychosis presentation 
(either current or historical, n=22); ii) needs indicate priority involvement of a CMHT, or 
other service not currently being provided (e.g. high risk, acutely unwell, n=14); iii) person 
offered therapy outside IAPT-SMI, therefore referral no longer relevant (n=9); iv) out of 
catchment area (n=2); vi) other (n=2). At the time of reporting, 84% of accepted referrals had 
opted-in (been contacted and agreed to an assessment for therapy). Of those opting in, 88% 
had completed an assessment. The time from referral to opt-in was 31 (SD=26) days, and 
from opt-in to assessment, 11 (SD=8) days. Referrals and attrition are illustrated in the 
service consort diagram in Figure 1. Demographic and clinical characteristics of those 
attending for an assessment are shown in Table 1. Therapy had been offered to 81% of people 
assessed with 65 closed cases: 54 (83%) completed therapy; 11 (17%) dropped out of therapy 
(received <5 sessions). For closed cases, the time from assessment to therapy was 39 
(SD=36) days. Completers received an average of 15.6 sessions (SD=7.4) over 5.8 months 
(SD=2.4). Those dropping out received 2.8 (SD=1.1) sessions over 2.2 (SD=1.3) months.  
 
Figure 1 and Table 1 here 
 
Primary clinical outcome (CHOICE) 
Paired completion rates for the CHOICE were 97% (n=63). Therapy completers improved 
during therapy, showing greater and more reliable improvement than dropouts, with higher 
final session scores (t=2.8, df=61, p=.006; Table 2). Two therapy completers showed reliable 
deterioration on the CHOICE (mean score reduced by ≥1.45): one reported high satisfaction, 
with unreliable improvement on the WEMWBS (mean score increased by <3), and unreliable 
deterioration on the CORE (mean score reduced by <5) and WSAS (mean score reduced by 
<13); one reported dissatisfaction, but showed meaningful improvement on the WEMWBS, 
and unreliable improvement on the CORE and WSAS. Neither showed any change in service 
use, functioning or PSYRATS scores.  
 
Table 2 here 
 
Service use 
Paired service use data were available for all participants. Average use/person/month in the 
year preceding therapy was 0.9 OBDs (SD=2.2) and 0.2 CTDs (SD=0.6). A quarter (24.6%) 
of closed cases had an admission and/or crisis team contact. Service use during therapy 
reduced to zero, with no difference for therapy completers compared to therapy dropouts 
(OBDs: unequal variances t=1.4, df=11.7, p=.2; CTDs: t=0.8, df=63, p=.4). Pre-post effect 
sizes were medium (n=65; OBDs: mean change=0.9, pooled SD=1.6, ES(d)=0.6; CTDs: 
mean change=0.2, Pooled SD=0.4, ES(d)=0.5).  
 
Functioning outcomes 
These were collected post-therapy for 61% of closed cases (n=40), all therapy completers 
(representing 74% (40/54) of those completing therapy). At the start of therapy, 35% of 
completers were engaged in meaningful activity. By the end of therapy, 48% were engaged in 
meaningful activity. Improvement (from unoccupied to meaningful activity) was reported by 
23% (n=9), no change for 67% (n=27), and a reduction in activity (from meaningful to 
unoccupied) for 10% (n=4). The change in scores did not reach significance (related samples 
McNemar test, p=.3).    
 
Satisfaction ratings  
These were completed by 61% of closed cases (n=40), again all therapy completers (Table 3). 
Mean total user experience score was 8.2 (SD=2.8, range 6 (highest possible) to 17). The 
pilot feedback group (n=29) rated the measures overall as helpful (Mean=6.9, SD=1.7), with 
only one ‘unhelpful’ (4) rating. 
 Table 3 here 
 
Secondary clinical outcomes  
Nearly 70% of closed cases (n=45) completed secondary clinical outcomes, all therapy 
completers (representing 83% of completers; Table 4). Just under half of closed cases 
reported recent psychotic symptoms (46%; n=30); 24 of these completed therapy; five 
therapy completers with psychotic symptoms did not complete secondary measures (21%). 
Therapy completion (χ2=0.4, df=1; p=.7), outcomes (F values <2.5; χ2 values <5.0; p values 
>.1) and satisfaction (t<0.5, df=37; χ2 values <3.5; p values >.3) did not differ according to 
psychotic symptom status.  
Table 4 here 
 
Access group and BME status 
Completion and dropout rates did not differ by access group (χ2=4.8, df=7, p=.7) or BME 
status (χ2=0.1, df=1, p=.7).  No outcome measure (CHOICE, service use, functioning, or 
secondary clinical outcomes) differed, at baseline, or in change from pre to post, according to 
access group or BME status (F values <4.1, p values >.05), nor did reliable improvement (χ2 
values <33, p values >.5). Experience and satisfaction ratings differed only on one item 
(understanding and addressing difficulties), with greater satisfaction for young BME men 
compared to older non-BME men and older BME women (F(7,32)=2.6, p=.03) and for BME 
service users overall (F(1,38)=8.2, p=.007; otherwise F values <3, p values >.1).  
 
 
Discussion 
Our aim was to demonstrate increased delivery of high quality, evidence-based, clinically and 
cost-effective, NICE- recommended, individual cognitive behavioural interventions for 
people with psychosis, in a routine secondary care setting, using a systematic, IAPT 
approach, with routine measurement of outcomes. 
 
We were able to use additional, ring-fenced funding to increase access almost threefold, and 
to increase delivery at a rate of approximately 20 cases/whole time equivalent therapist/year. 
The IAPT approach was feasible and acceptable to service users, with good satisfaction and 
experience ratings. High primary outcome paired completion rates (97%) provide some 
confidence in concluding that outcomes compare favourably to those reported for IAPT 
services for people with Common Mental Illnesses, with medium to large pre-post effect 
sizes across measures (e.g. Gyani et al., 2013; Clark et al., 2009). Pre-post change in 
secondary measures was comparable to other routine care studies (e.g. Peters et al., 2010;  
Morrison et al., 2004). Reductions in service use during therapy, consistent with previous 
findings, suggest cost-effectiveness. We have, therefore, demonstrated the potential for 
successful translation of the positive clinical and economic effects of therapy achieved in 
randomised controlled trials to routine services. Importantly, we demonstrated access to a 
group with rates of ethnic variation similar to those of our culturally diverse catchment areas, 
and found no demographic inequity in retention in therapy or in outcome.  
 
We consider three main factors to have facilitated increased access. Firstly, we were 
organisationally ready, with a history of strong clinical leadership in this area. Service 
pathways were established; equity of access, referral rates and outcomes were centrally 
monitored; and managerial support for specialised psychosis work, including the availability 
of expert training and supervision, had resulted in a critical mass of staff equipped to deliver 
interventions to a high standard. Our readiness meant that ring-fenced funding, the second 
key facilitator, could be translated almost immediately into increased delivery, and that the 
creation of secondary care posts dedicated solely to delivering NICE-recommended 
psychological interventions for people with psychosis was feasible. Therapist time was thus 
protected from the competing demands of crisis management and social care work in the 
CMHT, whilst preserving close working links. Finally, the specialised nature of the service 
meant that all staff, from assessors to supervisors, were knowledgeable about the difficulties 
facing people with psychosis, and how to accommodate these: for example, the need for 
persistent, yet flexible and sensitive efforts to engage; the use of reminders and prompts to 
promote attendance; and resilience to unpredictable attendance and engagement.  
 
We employed assistant psychologists to carry out therapy assessments, which reduced the 
burden on therapists, and the potential for completion of outcome measures to be 
deprioritised by therapists in the face of other clinical concerns. The independent assessment 
also acted as a useful triage system, reducing the amount of therapist time spent chasing 
referrals who eventually opted out of therapy. Attendance at post-therapy assessment sessions 
was good for completers (83%), but just under 70% for all closed cases, underlining the 
importance of reliable sessional measurement in achieving a high rate of paired outcomes. 
Service user feedback about the completion of outcome measures was generally positive; 
disseminating this information within our own service facilitated therapists overcoming their 
own reservations about outcome measurement.  
 
 Limitations 
The primary limitations of the evaluation are its service-specificity, and the uncontrolled 
design. Referrals were accepted on the basis of the service being suitable to meet their needs; 
not to represent a wider group, and the relatively small number of closed cases at this stage 
may limit the representativeness of the caseload even within the local context. The catchment 
area is urban, and some recommendations may be less applicable outside the inner city. 
Assessments were not blind, which may inflate effects, and the primary outcome measure is 
novel. Reported effects are pre-post and within-particpant, with no control group. We cannot, 
therefore, infer with any certainty that any changes in presentation occur as a result of 
therapy; nor can effects be compared directly with between-group single study and meta-
analytic effect sizes. Comparison between therapy completers and those who disengaged may 
be limited by additional difficulties of the disengaging group, unmeasured by our 
assessments. Bonferroni correction for multiple testing (four between-group; ten within-
participant tests of outcome) rendered two findings no longer significant; post-hoc 
calculations suggest that this may reflect lack of power (CHOICE improvement: n=63, 
adjusted alpha=.01, df=5; 80% power to detect χ2 values >15; PSYRATS-D: n=14; adjusted 
alpha=.005; 80% power to detect pre-post ES >1).  The between-group analyses of equity of 
access only had sufficient power to detect large effects, and the null findings should therefore 
be interpreted with caution, pending replication in larger samples.     
 
Implications 
The challenge of IAPT-SMI is to replicate at scale, in routine services, the effectiveness 
achieved under carefully controlled conditions in research trials by expert therapists, and to 
demonstrate both what has been delivered, and its impact. This is a difficult task: routine 
services are not research trials;  there are no clear inclusion criteria, service users present with 
complex, diagnostically indeterminate problems and staff work pragmatically and 
eclectically, using an admixture of published evidence, experience, and case by case science 
in practice. Nevertheless, our pilot has demonstrated that an IAPT-SMI approach, whereby 
psychological therapies are prioritised and systematically evaluated, can operate effectively 
within routine secondary services for people with psychosis, and can reliably evidence good 
outcomes. The implication for wider implementation is that increased access need not depend 
on a whole service transformation: our experience shows that once appropriate referral 
pathways and expert supervision/support structures are established, the recruitment of well 
trained therapists and assessors with ring-fenced time will result in increased, well evaluated, 
cost-effective delivery.  
 
Conclusions 
Outcomes from the first operational year of the SLaM IAPT-SMI demonstration site show 
that evidence-based, NICE-recommended individual psychological therapy interventions can 
be successfully delivered in routine services, with high paired completion rates and 
preliminary evidence for the translation of good clinical and economic outcomes. Primary 
facilitators were ring-fenced investment in competent therapy provision, adequate 
supervision, and trained assessors, in the context of established service pathways and 
governance structures, supported by strong clinical leadership and management. The 
framework delineated is potentially replicable to inform wider implementation and the 
delivery, at scale, of cost-effective individual interventions to improve recovery outcomes for 
people with psychosis.  
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Figure 1: Consort diagram showing referrals and retention over 14 months   
 
 
Table 1: Demographic and clinical characteristics of referrals 
Variable  All 
(n=221) 
 
Mean age in years (SD, range)  
 
37.9 (11.4, 18-70) 
 
Pathway  
 
Early Intervention 
Promoting Recovery 
 
 
 
 
53 (24%) 
168 (76%) 
 
Gender  
 
Male 
Female 
 
 
 
 
111 (50%) 
110 (50%) 
 
Ethnic group1 
 
Black/Minority Ethnic (BME) 
Non-BME 
 
 
 
 
 
 
127 (58%) 
93 (42%) 
 
Access group1   
Age ≤ 35 years 
Male BME 36 (16%) 
non-BME 22 (10%) 
Female BME 25 (11%) 
non-BME 13 (6%) 
Age > 35 years 
Male BME 23 (10%) 
non-BME 30 (14%) 
Female BME 43 (19%) 
non-BME 28 (13%) 
 
Diagnosis  
  
 
Schizophrenia spectrum (ICD F20-29) 
 
138 (62%) 
Bipolar (ICD F30/31) 18 (8%) 
Psychotic depression 26 (12%) 
Other 39 (18%) 
 
Key: 1One person preferred not to state their ethnicity; ICD: International Classification of 
Disease (World Health Organisation, 1992).  
Table 2: Primary clinical outcomes by therapy completion  
 Therapy complete 
(n=531) 
Therapy dropout 
(n=101) 
 Mean (SD) 
 
 Pre Post Pre Post 
CHOICE  4.8 (2.4) 6.4 (2.3) 4.6 (2.0) 4.2 (2.3) 
  Pooled SD 2.4 2.1 
  Pre-post t-test t=5.6, df=52, p<.001 t=0.9, df=9, p=.4  
  Change, ES 1.6 (2.0); ES:d=0.7(medium) 0.4 (1.5); ES:d=0.2(small) 
  Pooled SD 2.1 
  Between group t-test, ES  t=2.9, df=61, p=0.005, ES: d=0.6 (medium) 
 n (%) 
Any improvement 41 (77%) 4 (40%) 
Reliable Improvement2 29 (55%) 1 (10%) 
No change 2 (4%) 0 
Any deterioration 10 (19%) 6 (60%) 
Reliable Deterioration2 2 (4%) 2 (20%) 
Between group χ2test, ES χ2=11.4, df=5, p=.043, ES: Cramer’s V=0.4 (large) 
 
Key: 1n=1 did not complete a CHOICE in each group; 2a change in mean score of 1.45 or 
more on the CHOICE; 3no longer significant following Bonferroni correction; ES=Effect 
Size; SD=Standard deviation 
  
 
 
  
  
     
 
      
 
      
 
      
 
      
 
      
 
      
 
 
 
 
Table 3: Satisfaction ratings   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key:1n=39; 2n=41; 3FFT score for this service=83, based on 30 responses
Patient Experience Questionnaire and Satisfaction rating % responses (n=40) 
Patient Experience At all times Most of the time Sometimes Rarely/Never 
1. Did staff listen to you and treat your concerns seriously? 85 15 0 0 
2. Do you feel that the service has helped you to better 
understand and address your difficulties? 63 28 8 3 
3. Did you feel involved in making choices about your 
treatment and care? 60 30 10 0 
4. Were you satisfied with the time you waited for your first 
and subsequent appointments?1 72 21 8 0 
5. On reflection, did you get the help that mattered to you? 58 33 5 5 
6. Did you have confidence in your therapist and his/her skills 
and techniques? 85 13 3 0 
Satisfaction2 Very satisfied Satisfied Indifferent Dissatisfied 
How satisfied are you with therapy? 51 39 2 7 
Friends and Family Test (FFT) % responses (n=30)3 
How likely are you to recommend our service to friends and family if they needed similar care or treatment? 
Extremely likely Likely Neither likely nor unlikely Unlikely Extremely unlikely Don’t know 
83 17 0 0 0 0 
 Table 4: Secondary clinical outcomes 
 
 
Measure n 
Mean 
(SD) Pre-post change 
Pre-
therapy 
Post-
therapy 
Change 
(SD, pooled) Paired t-test ES (d) 
CORE-10 45 16.0 (8.9) 
10.8 
(7.1) 
5.2 
(8.4) t=6.1, df=44, p<.001 0.6 
WEMWBS 45 42.2 (12.9) 
50.4 
(9.7) 
8.2 
(12.0) t=6.0, df=44, p<.001 0.7 
WSAS 45 16.6 (9.8) 
12.8 
(10.3) 
4.2 
(10.2) t=3.0, df=44, p=.004 0.4 
PSYRATS-V 131 23.1 (8.6) 
16.6 
(10.9) 
6.5 
(10.1) t=1.7, df=12, p=.1 0.6 
PSYRATS-D 141 15.6 (3.6) 
11.5 
(6.3) 
4.1 
(5.4) t=2.8, df=13, p=.02
2
 0.8 
PSYRATS-
combined % 19
1
 
59.7 
(12.1) 
41.4 
(23.4) 
18.3 
(20.6) t=3.8, df=18, p=.001 0.9 
 
 
Key: CORE-10: Clinical Outcomes in Routine Evaluation (10 item) Barkham et al., 2013; 
WEMWBS: Warwick Edinburgh Mental Wellbeing Scale (Tennant et al., 2007); WSAS: Work 
and Social Adjustment Scale (Mundt et al., 2002); PSYRATS: Psychotic Symptoms Rating 
Scale (Haddock et al., 1999); V: Voices; D: Delusions; ES=Effect Size; SD=Standard 
deviation; 1includes n=8 experiencing both voices and delusions; 2no longer significant 
following Bonferroni correction. 
 
